Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

G. Reda, M. Riva, B. Fattizzo, R. Cassin, D. Giannarelli, M. Pennisi, A. Freyrie, R. Cairoli, A. Molteni, A. Cortelezzi

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)202-208
Number of pages7
JournalSeminars in Hematology
Volume55
Issue number4
DOIs
Publication statusPublished - 2018

Keywords

  • azacitidine, acute myeloid leukemia
  • adult
  • age
  • aged
  • blood toxicity
  • cancer prognosis
  • cancer risk
  • chronic myelomonocytic leukemia
  • controlled study
  • cytogenetics
  • drug safety
  • febrile neutropenia
  • female
  • high risk patient
  • human
  • infection
  • infection rate
  • intermediate risk patient
  • low risk patient
  • major clinical study
  • male
  • median survival time
  • multiple cycle treatment
  • myelodysplastic syndrome
  • myelofibrosis
  • overall survival
  • priority journal
  • retrospective study
  • Review
  • survival prediction
  • thrombocytopenia

Cite this